The list of awardees includes Donald Durden, MD, PhD, vice chair for research at University of California San Diego’s department of pediatrics. He won $1.6 million over four years for a phase 2 study of Poly-ICLC for the treatment of pediatric low grade gliomas. Grants were also given for treatments for stable sickle cell disease and multiple system atrophy, among others.
The program is administered through the FDA’s Orphan Products Grants Program, which aims to encourage the development of products for rare diseases.
More articles on FDA news:
FDA expands pilot program for electronic submission of 510(k) applications
The impact of FDA violations on stock price
FDA issues guidance for laboratory developed tests
